Puma Biotechnology Target of Unusually High Options Trading (PBYI)

Puma Biotechnology Inc (NASDAQ:PBYI) was the recipient of unusually large options trading on Monday. Stock traders acquired 8,565 call options on the stock. This represents an increase of Infinity compared to the average volume of 0 call options.

Puma Biotechnology (NASDAQ:PBYI) opened at $100.70 on Thursday. Puma Biotechnology has a twelve month low of $28.35 and a twelve month high of $136.90.

Puma Biotechnology (NASDAQ:PBYI) last posted its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.50) by $0.43. The company had revenue of $6.10 million during the quarter, compared to analyst estimates of $3.78 million. During the same quarter last year, the business posted ($1.11) EPS. equities analysts predict that Puma Biotechnology will post -8.36 EPS for the current fiscal year.

Several equities analysts recently weighed in on the company. J P Morgan Chase & Co reiterated a “buy” rating and set a $131.00 target price on shares of Puma Biotechnology in a research report on Wednesday, October 4th. Leerink Swann restated an “outperform” rating and issued a $125.00 price objective on shares of Puma Biotechnology in a report on Wednesday, August 2nd. Bank of America Corporation restated a “buy” rating and issued a $135.00 price objective (up from $117.00) on shares of Puma Biotechnology in a report on Monday, October 9th. Barclays PLC restated a “buy” rating and issued a $122.00 price objective (up from $103.00) on shares of Puma Biotechnology in a report on Friday, November 10th. Finally, Credit Suisse Group raised their price objective on Puma Biotechnology from $136.00 to $142.00 and gave the stock an “outperform” rating in a report on Friday, November 10th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the stock. Puma Biotechnology currently has an average rating of “Buy” and an average price target of $130.67.

In related news, SVP Richard Paul Bryce sold 15,000 shares of the stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $120.00, for a total transaction of $1,800,000.00. Following the transaction, the senior vice president now directly owns 42,239 shares in the company, valued at $5,068,680. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 21.10% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. Strs Ohio acquired a new stake in shares of Puma Biotechnology in the second quarter valued at about $122,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Puma Biotechnology in the second quarter valued at about $146,000. Kazazian Asset Management LLC acquired a new stake in shares of Puma Biotechnology in the second quarter valued at about $209,000. Teacher Retirement System of Texas acquired a new stake in shares of Puma Biotechnology in the second quarter valued at about $211,000. Finally, Ameritas Investment Partners Inc. grew its stake in shares of Puma Biotechnology by 5.9% in the second quarter. Ameritas Investment Partners Inc. now owns 2,522 shares of the biopharmaceutical company’s stock valued at $220,000 after buying an additional 140 shares in the last quarter. Institutional investors and hedge funds own 95.41% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Markets Daily and is owned by of Markets Daily. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2017/11/16/puma-biotechnology-target-of-unusually-high-options-trading-pbyi.html.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply